Screener
Nektar Therapeutics NKTR Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
|---|---|---|---|
| Total non-operating income (expense), net | (4,036) | (1,834) | |
| Loss before provision for income taxes and equity method investment | (43,090) | (46,369) | |
| Provision for income taxes | 64 | 52 | |
| Loss before equity method investment | (43,154) | (46,421) | |
| Loss from equity method investment | (1,750) | (4,461) | |
| Net loss | $ | $$(44,904) | (50,882) |
| Basic and diluted net loss per share | $ | $$(1.82) | (3.62) |
| Weighted average shares outstanding used in computing basic and diluted net loss per share | 24,736,066 | 14,063,402 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's net gains (losses) on investments?
- Nektar Therapeutics (NKTR) reported net gains (losses) on investments of -$1.75M in Q1 2026.
- How has Nektar Therapeutics's net gains (losses) on investments changed year-over-year?
- Nektar Therapeutics's net gains (losses) on investments increased by 60.8% year-over-year, from -$4.46M to -$1.75M.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Nektar Therapeutics's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude